GlassScriptPhysician profile
Kevin Turner
NPI 1518995208
$8,788.38
in general payments reported to CMS, 2019-2025
21 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $169 · 2021: $235 · 2022: $2,316 · 2023: $1,954 · 2024: $1,581 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,038 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,037.91 |
| Education | $298.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $1,096.00 | 2022-2023 | Zimhi, Lucemyra |
| Teva Pharmaceuticals USA, INC. | $1,095.14 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $951.76 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $874.46 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $830.49 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $669.68 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $622.80 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $496.72 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $442.71 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Indivior INC. | $366.91 | 2022-2024 | Perseris |
| Alkermes, INC. | $295.40 | 2019-2022 | |
| Allergan, INC. | $254.84 | 2019 | |
| Axsome Therapeutics, INC. | $207.42 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $129.64 | 2022-2023 | Trintellix |
| Neuronetics, INC. | $115.74 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $99.74 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $67.36 | 2023-2024 | Qelbree, Qelbree |
| Bioxcel Therapeutics, INC. | $54.83 | 2023 | Igalmi |
| Vanda Pharmaceuticals INC. | $51.84 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $46.06 | 2022 | |
| Tris Pharma INC | $18.84 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.